Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published March 2011
  • Article
  • Info & Metrics
  • PDF
Loading

PI3K/AKT/mTOR Inhibitors in Patients with PIK3CA Mutations

Janku et al., Page 558

Activating mutations of the p110 subunit of phosphatidylinositol-3-kinase (PIK3CA) have been identified in a broad spectrum of tumors. Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. In a pilot study, Janku and colleagues show for the first time that selecting patients with PIK3CA mutations for treatment with PI3K/AKT/mTOR inhibitors results in high rates of response, even in the early clinical trials setting. Because PIKC3A mutations are one of the most common mutations in cancer, this work is potentially applicable to a large number of patients and also provides early proof-of-principle for the concept of personalized targeted therapy in cancer treatment.

NCI-60 miRNA Analysis ENMD-2076, an Aurora and Angiogenic Kinase Inhibitor

Søkilde et al., Page 375

The NCI-60 cell panel has been well characterized with respect to drug sensitivity, genomic, transcriptomic, and proteomic data. Here, Søkilde and colleagues provide a comprehensive analysis of the NCI-60 microRNA landscape by measuring the expression of 955 microRNAs (miRNA) by an LNA-enhanced microarray. The miRNA expression data were correlated to drug sensitivity, mRNA, and protein levels, as well as to tissue of origin. The analysis, which includes a large supplementary data set, may aid in investigation of miRNAs associated with tumor biology, drug resistance, and sensitivity, and thus help identification of new molecular targets and miRNA based biomarkers for personalized medication.

Second Generation of mTOR Inhibitors

Vilar et al., Page 395

Rapalogs have integrated the first wave of mTOR inhibitors developed for the treatment of different malignancies, presenting a relative lack of clinical activity. In this article, Vilar and colleagus review the most recent advances in the understanding of the molecular biology of this pathway, mainly the characterization of the dual nature of the mTOR complex and the intricate network of feedback loops that regulates it. These findings have allowed the development of a promising second generation of inhibitors that are currently in early stages of clinical development and whose results are summarized in this article.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (3)
March 2011
Volume 10, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther March 1 2011 (10) (3) 373;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther March 1 2011 (10) (3) 373;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • PI3K/AKT/mTOR Inhibitors in Patients with PIK3CA Mutations
    • NCI-60 miRNA Analysis ENMD-2076, an Aurora and Angiogenic Kinase Inhibitor
    • Second Generation of mTOR Inhibitors
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement